Last reviewed · How we verify
Dydrogesterone M ( case 2 )
Dydrogesterone M ( case 2 ) is a Progestin Small molecule drug developed by Trieu, Nguyen Thi, M.D.. It is currently FDA-approved for Threatened or habitual miscarriage due to progesterone deficiency, Luteal phase support in assisted reproductive technology, Menstrual disorders and endometriosis. Also known as: Dydrogesterone M.
Dydrogesterone is a synthetic progestin that binds to progesterone receptors to support luteal phase function and maintain pregnancy.
Dydrogesterone is a synthetic progestin that binds to progesterone receptors to support luteal phase function and maintain pregnancy. Used for Threatened or habitual miscarriage due to progesterone deficiency, Luteal phase support in assisted reproductive technology, Menstrual disorders and endometriosis.
At a glance
| Generic name | Dydrogesterone M ( case 2 ) |
|---|---|
| Also known as | Dydrogesterone M |
| Sponsor | Trieu, Nguyen Thi, M.D. |
| Drug class | Progestin |
| Target | Progesterone receptor |
| Modality | Small molecule |
| Therapeutic area | Obstetrics/Gynecology |
| Phase | FDA-approved |
Mechanism of action
Dydrogesterone is a retro-isomer of norethisterone with selective progesterone receptor agonist activity. It mimics the effects of endogenous progesterone, promoting endometrial secretion and maintaining uterine quiescence during pregnancy. It is used to prevent miscarriage and support early pregnancy in women with progesterone deficiency.
Approved indications
- Threatened or habitual miscarriage due to progesterone deficiency
- Luteal phase support in assisted reproductive technology
- Menstrual disorders and endometriosis
Common side effects
- Headache
- Nausea
- Breast tenderness
- Dizziness
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dydrogesterone M ( case 2 ) CI brief — competitive landscape report
- Dydrogesterone M ( case 2 ) updates RSS · CI watch RSS
- Trieu, Nguyen Thi, M.D. portfolio CI
Frequently asked questions about Dydrogesterone M ( case 2 )
What is Dydrogesterone M ( case 2 )?
How does Dydrogesterone M ( case 2 ) work?
What is Dydrogesterone M ( case 2 ) used for?
Who makes Dydrogesterone M ( case 2 )?
Is Dydrogesterone M ( case 2 ) also known as anything else?
What drug class is Dydrogesterone M ( case 2 ) in?
What development phase is Dydrogesterone M ( case 2 ) in?
What are the side effects of Dydrogesterone M ( case 2 )?
What does Dydrogesterone M ( case 2 ) target?
Related
- Drug class: All Progestin drugs
- Target: All drugs targeting Progesterone receptor
- Manufacturer: Trieu, Nguyen Thi, M.D. — full pipeline
- Therapeutic area: All drugs in Obstetrics/Gynecology
- Indication: Drugs for Threatened or habitual miscarriage due to progesterone deficiency
- Indication: Drugs for Luteal phase support in assisted reproductive technology
- Indication: Drugs for Menstrual disorders and endometriosis
- Also known as: Dydrogesterone M
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing